# US 2021/0177962 A1 · Mva vaccine for delivery of a ul128 complex and preventing cmv infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0177962 A1
- Document ID: US20210177962A1
- Status: Published application
- Kind: A1
- Application number: 17/100,573
- Filed: 2020-11-20
- Published: 2021-06-17
- Earliest claimed: 2012-07-27
- Assignees: City of Hope
- Applicants: City of Hope
- Inventors: Don J. DIAMOND; Felix WUSSOW
- Web page: https://patentgrep.com/patent/US20210177962A1

## CPC

- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2710/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2799/023: where the vector is derived from a poxvirus
- C12N 2800/204: of bacterial origin, e.g. BAC
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM/gN or gO.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for treating a CMV infection in a subject comprising: administering to the subject a therapeutically effective amount of a CMV vaccine, and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof,
wherein the CMV vaccine comprises a viral vector capable of expressing CMV proteins or antigenic fragments thereof that form a UL128 complex; and wherein the viral vector is derived from a poxvirus,
thereby treating a CMV infection in the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein the viral vector is derived from an Avipoxvirus, an Orthopoxvirus, or a Parapoxvirus.

### Claim 23 (depends on 22)

The method of claim 22, wherein the viral vector is a modified vaccina Ankara (MVA) vector.

### Claim 24 (depends on 21)

The method of claim 21, wherein the UL128 complex comprises a set of five CMV proteins or antigenic fragments thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the set of five CMV proteins or antigenic fragments thereof comprises UL128, UL130, UL131A, gL, and gH.

### Claim 26 (depends on 21)

The method of claim 21, wherein the viral vector further comprises one or more DNA sequences that encode additional CMV proteins or antigenic fragments thereof selected from pp65, gB or both.

### Claim 27 (depends on 21)

The method of claim 21, wherein the CMV infection is a congenital CMV infection.

### Claim 28

A method of vaccinating a subject against a CMV infection comprising: administering to the subject a therapeutically effective amount of a CMV vaccine, and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof,
wherein the CMV vaccine comprises a viral vector capable of expressing CMV proteins or antigenic fragments thereof that form a UL128 complex, and wherein the viral vector is derived from a poxvirus,
thereby vaccinating the subject.

### Claim 29 (depends on 28)

The method of claim 28, wherein vaccinating the subject comprises inducing an immune response against a CMV infection.

### Claim 30 (depends on 29)

The method of claim 29, wherein inducing an immune response comprises inducing the production of neutralizing antibody and/or reducing viral load in the subject.

### Claim 31 (depends on 28)

The method of claim 28, wherein the viral vector is a modified vaccina Ankara (MVA) vector.

### Claim 32 (depends on 28)

The method of claim 28, wherein the UL182 complex comprises a set of five CMV proteins or antigenic fragments thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein the set of five CMV proteins or antigenic fragments thereof comprises UL128, UL130, UL131A, gL, and gH.

### Claim 34 (depends on 28)

The method of claim 28, wherein administering a CMV vaccine comprise administering two doses of the CMV vaccine to the subject.

### Claim 35 (depends on 34)

The method of claim 34, wherein the two doses are administered at a 6-week interval.

### Claim 36

A method of inhibiting horizontal and/or vertical transmission of a CMV infection by a subject comprising: administering to the subject a therapeutically effective amount of a CMV vaccine, and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof,
wherein the CMV vaccine comprises a viral vector capable of expressing CMV proteins or antigenic fragments thereof that form a UL128 complex, and wherein the viral vector is derived from a poxvirus,
thereby inhibiting horizontal and/or vertical transmission of a CMV infection by a subject.

### Claim 37 (depends on 36)

The method of claim 36, wherein inhibiting horizontal and/or vertical transmission comprises inducing the production of neutralizing antibody and/or reducing viral load in the subject.

### Claim 38 (depends on 36)

The method of claim 36, wherein the viral vector is a modified vaccina Ankara (MVA) vector.

### Claim 39 (depends on 36)

The method of claim 36, wherein the UL182 complex comprises a set of five CMV proteins or antigenic fragments thereof.

### Claim 40 (depends on 39)

The method of claim 39, wherein the set of five CMV proteins or antigenic fragments thereof comprises UL128, UL130, UL131A, gL, and gH.
